EBV Variant Detection for Nasopharyngeal Carcinoma Risk Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for early diagnosis and risk assessment of nasopharyngeal carcinoma (NPC) are inadequate, particularly in high-risk geographic areas, due to the complex geographic and viral factors involved, such as Epstein-Barr virus (EBV) variants, which have not been effectively linked to the disease's pathogenesis.
Innovation Solution
A method involving genomic sequencing and analysis of EBV variants from saliva samples to identify specific single nucleotide polymorphisms (SNPs) and indels associated with NPC, allowing for the determination of genetic risk scores and early detection of the disease through a kit containing reagents for detecting these risk alleles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genomic sequencing and analysis of EBV variants is performed to identify specific SNPs and indels associated with NPC, then measurement precision of risk assessment is improved, but device complexity and cost increase
Solution Approach 1:
The patent segments the complex genomic analysis into specific target regions (SNPs and indels in EBV genomic sequence) that are most strongly associated with NPC. Instead of sequencing the entire genome, the method focuses on specific high-risk variants identified through cluster analysis, thereby reducing complexity while maintaining precision.
Solution Approach 2:
The patent performs preliminary genome-wide association studies and cluster analysis to identify specific SNPs and indels that are strongly associated with NPC before developing the diagnostic method. This preliminary action allows the final diagnostic tool to focus only on the most relevant genetic markers, simplifying the testing process while maintaining high precision.
2Reliability
If EBV variants with high genetic risk score are identified through genome-wide association study, then reliability of NPC risk prediction is improved, but loss of time and resources in sequencing increases
Solution Approach 1:
The patent extracts only the most significant SNPs and indels from the complete EBV genomic sequence that show strong association with NPC through genome-wide association studies. By focusing on these specific high-risk variants rather than analyzing the entire genome, the method achieves reliable risk prediction with reduced sequencing time and resource consumption.
Solution Approach 2:
The patent applies local quality by differentiating between high-risk and low-risk EBV variants based on specific genomic characteristics (SNPs and indels). Rather than treating all EBV variants uniformly, the method identifies and focuses on local regions of the genome that have the highest predictive value for NPC, improving efficiency and reliability.
3Loss of information
If cluster analysis is used to discover EBV subgroups among population carriers, then understanding of viral pathogenesis is improved, but device complexity and analytical requirements increase
Solution Approach 1:
The patent uses cluster analysis to dynamically group EBV variants into distinct subgroups (1A-C and 2A-B) based on their genomic characteristics and association with NPC. This dynamic classification system allows for better understanding of viral pathogenesis by identifying which subgroups are most strongly associated with the disease, while the clustering algorithm handles the complexity of analyzing multiple variants simultaneously.
Data Source
AI summary
The present invention provides novel Epstein Barr virus (EBV) variants including those associated with increased risk for developing nasopharyngeal carcinoma (NPC).